Synthetic Biology News

The potential of cytokines as immunotherapies is limited by their systemic toxicity, therefore, new engineering approaches aim at modifying cytokines for tumor-targeted reconstitution of their activity, providing new opportunities for their use in combina

Learn how scientists at the Pritzker School of Molecular Engineering, University of Chicago, have engineered a masked Interleukin-12 protein that is preferentially unmasked at tumor sites, thereby reducing adverse events commonly associated with systemic

Learn how a new platform to regulate CAR T cell activity offers total control, enabling the complete silencing of CAR signaling.

Learn about a new CRISPR/Cas9 application leveraging its RNA guided specificity to self-assemble peptide fused and inactivated Cas9 onto DNA microarrays.

Learn how lentiviral vectors promise to offer a safer gene delivery approach for correction of immunological deficits in SCID-ADA.

Learn how an influenza hemagglutinin nanoparticle vaccine protects against influenza viral strains by inducing broad neutralizing antibodies.

Learn how structure-guided modifications to CRISPR/Cas12a and Cas9 in the Kleinstiver lab have expanded access to genome sequences by expanding PAM preferences.

Learn how high throughput DNA assembly helps expedite metabolic engineering for biofuel pathway optimization in microbes.

Learn about how alanine scanning mutagenesis helps to map amino acid residues essential for protein functions and protein-protein interactions facilitating immunogen and antibody design and supporting therapeutic development.

Driving Antibody Development through Improved Engineering Technologies